Abstracts tagged "Systemic sclerosis"

Abstract Number: 1830 • 2019 ACR/ARP Annual Meeting
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth Volkmann¹, Virginia Steen ², Ning Li ³, Michael Roth ⁴, Philip Clements ³, Dinesh Khanna ⁵, Daniel Furst ⁶, Shervin Assassi ⁷, Grace Kim ³, Jonathan Goldin ³, Robert Elashoff ³ and Donald Tashkin ³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²Georgetown University, Washington, D.C., USA, Georgetown, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁶University of California, Los Angeles, CA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: Observational studies have demonstrated that African American (AA) patients with systemic sclerosis (SSc) have a more unfavorable prognosis compared with non-AA. However, no studies…
Abstract Number: 2602 • 2019 ACR/ARP Annual Meeting
Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis
Anna Maria Hoffmann-Vold¹, Håvard Fretheim ², Brian Chung ³, Henriette Didriksen ³, Espen Bækkevold ³, Øyvind Midtvedt ³, Cathrine Brunborg ³, Kristian Holm ³, Anders Tennøe ³, Torhild Garen ³, Tore Midtvedt ⁴, Marius Trøseid ³, Johannes Hov ³, Knut Lundin ³ and Øyvind Molberg ², ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²University Hospital Oslo, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: In the double-blind, placebo-controlled 16-week pilot including 10 systemic sclerosis (SSc) patients with upper and lower gastrointestinal (GI) symptoms we found that fecal microbiota…
Abstract Number: 2914 • 2019 ACR/ARP Annual Meeting
Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)
Silvia Bellando-Randone¹, Gemma Lepri ¹, Dorte Huscher ², Tunde Minier ³, Serena Guiducci ⁴, Cosimo Bruni ¹, Laszlo Czirjak ³, Maurizio Cutolo ⁵, Vanessa Smith ⁶, Jerome Avouac ⁷, Daniel Furst ⁸, Yannick Allanore ⁷, Oliver Distler ⁹ and Marco Matucci-Cerinic ¹⁰, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Charitè-Universitaetsmedizin Berlin, Berlin, Germany, ³University of Pecs, Pecs, Hungary, ⁴Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁶Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁷Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁸University of California, Los Angeles, CA, ⁹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ¹⁰University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: The very early diagnosis of SSc is a challenge today. The aim of the VEDOSS project was to study in an at-risk population, the…
Abstract Number: 711 • 2019 ACR/ARP Annual Meeting
Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ², Jison Hong ¹, Khushboo Sheth ¹ and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease with peripheral manifestations including arthritis, tendinopathy, sclerodactyly, contractures, calcinosis, acroosteolysis, and vascular disease which…
Abstract Number: 737 • 2019 ACR/ARP Annual Meeting
The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Ning Li ², Grace Kim ², Jonathan Goldin ², Maureen Mayes ⁴, Julio Charles ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Robert Elashoff ² and Shervin Assassi ⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁵University of Texas, Houston, Houston, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) affects the majority of patients with systemic sclerosis (SSc). The disease course of ILD varies among SSc patients and no…
Abstract Number: 1051 • 2019 ACR/ARP Annual Meeting
Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis
Tamar Wheeler¹, Ji-Qing Chen ¹, Diana Toledo ¹, Bhaven Mehta ², Yue Wang ², Meredith Brown ¹, Rajan Bhandari ³ and Mengqi Huang ⁴, ¹Dartmouth College, Hanover, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth College, Lebanon, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH
Background/Purpose: Although the majority of SSc research has focused on differential gene expression, recent studies havedemonstrated that non-coding epigenetic changes in chromatin accessibility are likely…
Abstract Number: 1637 • 2019 ACR/ARP Annual Meeting
The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy
Masanari Kodera¹, Yoshihito Tanaka ², Yumi Ito ², Miho Sugata ², Satoko Hisada ², Naohisa Ichiki ² and Toshiaki Tanabe ², ¹Japan Community Health care Organization Chukyo Hospital, Department of Dermatology and Rheumatology, Aichi, Japan, ²Japan Community Health care Organization Chukyo hospital, Nagoya, Japan
Background/Purpose: Systemic Sclerosis (SSc) patients with anti-RNA polymerase III (RNAP) antibody have been reported to have an increased risk of malignancy as compared with those…
Abstract Number: 1832 • 2019 ACR/ARP Annual Meeting
Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis
Yasser Radwan¹, Reto Kurmann ², Avneek Singh Sandhu ³, Cynthia Crowson ⁴, Eric Matteson ⁵, Thomas Osborn ¹, Kenneth Warrington ², Rekha Mankad ¹ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic Rochester, rochester, MN, ³kettering health, dayton, OH, ⁴Mayo Clinic Rochester, Rochester, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Most cardiovascular (CV) risk calculators including the Framingham risk score (FRS) and American College of Cardiology (ACC) / American Heart Association (AHA) risk score…
Abstract Number: 2603 • 2019 ACR/ARP Annual Meeting
Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Anna-Maria Hoffmann-Vold¹, Yannick Allanore ², Margarida Alves ³, Nicole Graf ⁴, Paolo Airò ⁵, Lidia P. Ananyeva ⁶, László Czirják ⁷, Serena Guiducci ⁸, Eric Hachulla ⁹, Mengtao Li ¹⁰, Carina Mihai ¹¹, Gabriela Riemekasten ¹², Petros Sfikakis ¹³, Gabriele Valentini ¹⁴, Otylia Kowal-Bielecka ¹⁵ and Oliver Distler ¹⁶, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland, Winterthur, Switzerland, ⁵UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy, ⁶VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁸Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁹Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ¹⁰Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic), ¹¹Dept. of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Dept. of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, ¹³Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁴Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ¹⁵Dept. of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, Bialystok, Poland, ¹⁶Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is heterogeneous; some patients may experience rapid decline in lung function, while others have relatively…
Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Bhaven Mehta ¹, Jennifer Franks ¹, Yiwei Yuan ², Yue Wang ¹, Veronica Berrocal ³, Tammara Wood ¹, Cathie Spino ⁴, David Fox ⁵, Dinesh Khanna ⁶ and Michael Whitfield⁷, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Hanover, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁷Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH
Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…
Abstract Number: 713 • 2019 ACR/ARP Annual Meeting
NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity
Francesca Pignataro ¹, Antonina Minniti ¹, Wanda Maglione ¹, Francesco Campanaro ¹, Domenico Sambataro ², Gianluca Sambataro ², Claudio Vitali ³ and Nicoletta Del Papa¹, ¹UOC Day Hospital Reumatologia, ASST Gaetano Pini, Milan, Italy, ²Istituto ArtroReuma, Catania, Italy, ³Sezione di Reumatologia, Istituto San Giuseppe, Como, Italy
Background/Purpose: We previously demonstrated that NEMO score, i.e., the cumulative number of microhaemorrhages (MHEs) and microthrombosis (MTs) observed in nailfold videocapillaroscopy (NVC), was a good…
Abstract Number: 738 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis
Giacomo De Luca¹, Silvia Bosello ², Corrado Campochiaro ¹, Silvia Sartorelli ³, Giovanni Peretto ⁴, Simone Sala ⁵, Giovanni Canestrari ², Gaetano Thiene ⁶, Cristina Basso ⁶, Paolo Della Bella ⁴, Elisa Gremese ⁷ and Lorenzo Dagna ¹, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Rheumathology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital, Mialn, Italy, ⁶Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, ⁷Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Background/Purpose: Myocarditis is a life-threatening inflammatory disease increasingly reported in Systemic Sclerosis(SSc); the histological, clinical and prognostic features of SSc-myocardits have not been elucidated yet.…
Abstract Number: 1052 • 2019 ACR/ARP Annual Meeting
The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension
Emma Derrett-Smith ¹, Kristina Clark¹, Shiwen Xu ¹, David Abraham ¹, Olivier Lacombe ², Pierre Broqua ², Jean-Louis Junien ², Irena Konstantinova ² and Christopher Denton ³, ¹University College London, London, United Kingdom, ²Inventiva, Daix, France, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: The TβRIIΔk-fib transgenic mouse model of systemic sclerosis (SSc) develops constitutive structural vasculopathy with vessel wall fibrosis and is susceptible to pulmonary hypertension (PH)…
Abstract Number: 1638 • 2019 ACR/ARP Annual Meeting
Sexual Health in 60 Female Patients with Systemic Sclerosis
Barbora Hermankova ¹, Maja Spiritovic ², Hana Storkanova ³, Sabina Oreska ⁴, Petr Cesak ¹, Karel Pavelka ⁴, Jiří Vencovský ⁴, Ladislav Senolt ⁴, Radim Becvar ⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is a chronic, multisystem, connective tissue disorder characterized by fibrosis of the skin and internal organ involvement, which can influence all…
Abstract Number: 1834 • 2019 ACR/ARP Annual Meeting
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Ning Li ², Elizabeth Volkmann ³, Maureen Mayes ¹, Jun Ying ⁴, Michael Roth ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Jonathan Goldin ², Robert Elashoff ² and Donald Tashkin ², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].